• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Arimidex (anastrozole)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Arimidex (anastrozole)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Arimidex has been approved as a treatment for advanced breast cancer in postmenopausal women whose disease has progressed following therapy with tamoxifen.

    Clinical Results

    The FDA made its decision after evaluating results of clinical studies involving more than 750 subjects. Results from the two studies showed that Arimidex is effective in the treatment of advanced breast cancer.

    Side Effects

    Most commonly reported side effects, regardless of causality, included fatigue, nausea, headache, hot flashes, pain and back pain. Arimidex is not associated with significant weight gain reported with progestins.

    Mechanism of Action

    Results from studies suggest that growth of some breast cancer tumors is stimulated by the female hormone estrogen. Arimidex, a nonsteroidal compound, is the first entry in a new class of third-generation selective oral aromatase inhibitors. Inhibition of aromatase reduces the production of estrogen. Thus, Arimidex reduces serum concentration of estrogen, an effect that has been shown to be of benefit in postmenopausal women with breast cancer.

    Additional Information

    Approximately one woman in eight will develop breast cancer in her lifetime. According to the American Cancer Society, an estimated 184,300 women will be diagnosed with breast cancer in 1996. It is estimated that about 6% of patients with breast cancer in the United States. have advanced breast cancer.

    Approval Date: 1996-01-01
    Company Name: AstraZeneca
    Back to Listings

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing